News
SEPN
48.19
+0.90%
0.43
Septerna Reaches Analyst Target Price
NASDAQ · 15h ago
Septerna Is Maintained at Overweight by Wells Fargo
Dow Jones · 16h ago
Septerna Price Target Raised to $50.00/Share From $48.00 by Wells Fargo
Dow Jones · 16h ago
Wells Fargo Maintains Overweight on Septerna, Raises Price Target to $50
Benzinga · 16h ago
Septerna, Inc. (SEPN) Receives a Buy from Wells Fargo
TipRanks · 17h ago
Analysts Conflicted on These NA Names: Septerna, Inc. (SEPN) and Douglas AG (OtherDOUDF)
TipRanks · 18h ago
Septerna Price Target Raised to $60.00/Share From $40.00 by HC Wainwright & Co.
Dow Jones · 18h ago
Septerna Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 18h ago
Wall Street Analysts Are Bullish on Top NA Picks
TipRanks · 20h ago
Septerna Is Maintained at Buy by Guggenheim
Dow Jones · 1d ago
Guggenheim Maintains Buy on Septerna, Raises Price Target to $51
Benzinga · 1d ago
Analysts Offer Insights on NA Companies: Septerna, Inc. (SEPN) and Rapid7 (RPD)
TipRanks · 1d ago
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 2d ago
Press Release: Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
Dow Jones · 2d ago
Press Release: Septerna Highlights Business -2-
Dow Jones · 2d ago
Weekly Report: what happened at SEPN last week (0803-0807)?
Weekly Report · 2d ago
Septerna's First Profitable Quarter Could Redefine What Kind of Biotech This Is
Barchart · 5d ago
3 Small-Cap Stocks Analysts Expect to Rally Big
TipRanks · 08/04 15:51
Weekly Report: what happened at SEPN last week (0727-0731)?
Weekly Report · 08/03 09:40
Weekly Report: what happened at SEPN last week (0720-0724)?
Weekly Report · 07/27 09:43
More
Webull provides a variety of real-time SEPN stock news. You can receive the latest news about Septerna, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.